{"success":true,"data":{"pressRelease":{"id":"140339","rtpr_id":"nPn8GXMSTa-20260910","ticker":"CMPS","exchange":"NASDAQ","all_tickers":["CMPS"],"title":"Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training","author":"PR Newswire","published_at":"2026-09-10T12:00:16.432Z","article_body":"Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training\n\nPR Newswire\n\nNEW YORK, Sept. 10, 2026\n\nNew certificate program will prepare clinicians to support patients receiving\nCOMP360 psilocybin treatment, if approved by the FDA\n\nNEW YORK, Sept. 10, 2026 /PRNewswire/ -- Fluence, a leading provider of\nprofessional education in psychedelic therapy, today announced that it has\nbeen selected by Compass Pathways plc (Nasdaq: CMPS) as a recipient of its\nU.S. healthcare provider training grant program. Through the collaboration,\nFluence is developing a new certificate program designed to prepare healthcare\nproviders to deliver high-quality care for patients receiving\nCOMP360 psilocybin treatment, if approved by the U.S. Food and Drug\nAdministration (FDA).\n\nCOMP360 is an investigational synthetic psilocybin treatment currently being\nevaluated for treatment-resistant depression. In anticipation of potential FDA\napproval and subsequent commercial availability, the Post-Approval COMP360\nPsilocybin Certificate Program will prepare clinicians with the knowledge and\nskills required to support patients throughout the COMP360 treatment\nexperience. The program will combine Fluence's experience training thousands\nof clinicians in psychedelic therapy with Compass Pathways' clinical guidance\nfor COMP360.\n\nThe certificate program will progress through three modules: Foundations of\nPsychedelic Care, Understanding Psilocybin, and COMP360 Certification.\nClinicians will build foundational skills for supporting patients through\npsychedelic treatment, develop an understanding of psilocybin and the research\nbehind its therapeutic use, and receive COMP360-specific training covering the\ncompound, applicable regulations, patient preparation, treatment\nadministration, and follow-up.\n\n\"This is a moment Fluence has been preparing for since our earliest days,\"\nsaid Elizabeth Nielson, PhD, Chief Executive Officer and Co-Founder of\nFluence. \"Our goal has always been to help clinicians translate rigorous\npsychedelic research into safe, skilled and evidence-based clinical practice.\nWorking with Compass to prepare providers for the potential introduction of\nCOMP360 allows us to bring together years of clinician education and clinical\nresearch training in a program designed for real-world care.\"\n\nFluence was a training partner selected by Compass Pathways through a\ncompetitive process based on expertise in psychedelic training design,\ndelivery and governance, ability to scale, commitment to access and inclusion,\nand regulatory alignment.\n\nIn addition to training individual clinicians, Fluence supports healthcare\norganizations preparing and managing clinical workforces at scale. Through its\ntraining operations platform, organizations can enroll providers and access\nreal-time data on training progress, completion, competency and credentialing,\nproviding the visibility and documentation needed to develop a consistently\ntrained and verifiably prepared workforce.\n\nTo pre-enroll or learn more visit our website\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766557-1&h=1563907107&u=https%3A%2F%2Fwww.fluencetraining.com%2Ftraining%2Fpost-approval-comp360-program&a=website)\n.\n\nAbout Fluence\n\nFluence builds the human capabilities required for psychedelic and\nneuroplastogen care. Through evidence-based training, expert instruction,\nexperiential practice and competency assessment, Fluence prepares clinicians\nto deliver high-quality care and enables organizations to develop competent,\nconsistently trained and verifiably prepared providers. Fluence's programs are\ngrounded in clinical research and designed for the realities and\nresponsibilities of clinical practice. www.fluencetraining.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766557-1&h=4187276432&u=http%3A%2F%2Fwww.fluencetraining.com%2F&a=www.fluencetraining.com)\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training-302875218.html\n(https://www.prnewswire.com/news-releases/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training-302875218.html)\n\nSOURCE Fluence International, Inc.\n\n\n\nmedia@fluencetraining.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1980975/fluence_header_logo.jpg?id=OA2927665\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn8GXMSTa-20260910","title":"Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training","author":"PR Newswire","ticker":"CMPS","created":"2026-09-10T12:00:16.432Z","tickers":["CMPS"],"exchange":"NASDAQ","article_body":"Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training\n\nPR Newswire\n\nNEW YORK, Sept. 10, 2026\n\nNew certificate program will prepare clinicians to support patients receiving\nCOMP360 psilocybin treatment, if approved by the FDA\n\nNEW YORK, Sept. 10, 2026 /PRNewswire/ -- Fluence, a leading provider of\nprofessional education in psychedelic therapy, today announced that it has\nbeen selected by Compass Pathways plc (Nasdaq: CMPS) as a recipient of its\nU.S. healthcare provider training grant program. Through the collaboration,\nFluence is developing a new certificate program designed to prepare healthcare\nproviders to deliver high-quality care for patients receiving\nCOMP360 psilocybin treatment, if approved by the U.S. Food and Drug\nAdministration (FDA).\n\nCOMP360 is an investigational synthetic psilocybin treatment currently being\nevaluated for treatment-resistant depression. In anticipation of potential FDA\napproval and subsequent commercial availability, the Post-Approval COMP360\nPsilocybin Certificate Program will prepare clinicians with the knowledge and\nskills required to support patients throughout the COMP360 treatment\nexperience. The program will combine Fluence's experience training thousands\nof clinicians in psychedelic therapy with Compass Pathways' clinical guidance\nfor COMP360.\n\nThe certificate program will progress through three modules: Foundations of\nPsychedelic Care, Understanding Psilocybin, and COMP360 Certification.\nClinicians will build foundational skills for supporting patients through\npsychedelic treatment, develop an understanding of psilocybin and the research\nbehind its therapeutic use, and receive COMP360-specific training covering the\ncompound, applicable regulations, patient preparation, treatment\nadministration, and follow-up.\n\n\"This is a moment Fluence has been preparing for since our earliest days,\"\nsaid Elizabeth Nielson, PhD, Chief Executive Officer and Co-Founder of\nFluence. \"Our goal has always been to help clinicians translate rigorous\npsychedelic research into safe, skilled and evidence-based clinical practice.\nWorking with Compass to prepare providers for the potential introduction of\nCOMP360 allows us to bring together years of clinician education and clinical\nresearch training in a program designed for real-world care.\"\n\nFluence was a training partner selected by Compass Pathways through a\ncompetitive process based on expertise in psychedelic training design,\ndelivery and governance, ability to scale, commitment to access and inclusion,\nand regulatory alignment.\n\nIn addition to training individual clinicians, Fluence supports healthcare\norganizations preparing and managing clinical workforces at scale. Through its\ntraining operations platform, organizations can enroll providers and access\nreal-time data on training progress, completion, competency and credentialing,\nproviding the visibility and documentation needed to develop a consistently\ntrained and verifiably prepared workforce.\n\nTo pre-enroll or learn more visit our website\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766557-1&h=1563907107&u=https%3A%2F%2Fwww.fluencetraining.com%2Ftraining%2Fpost-approval-comp360-program&a=website)\n.\n\nAbout Fluence\n\nFluence builds the human capabilities required for psychedelic and\nneuroplastogen care. Through evidence-based training, expert instruction,\nexperiential practice and competency assessment, Fluence prepares clinicians\nto deliver high-quality care and enables organizations to develop competent,\nconsistently trained and verifiably prepared providers. Fluence's programs are\ngrounded in clinical research and designed for the realities and\nresponsibilities of clinical practice. www.fluencetraining.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4766557-1&h=4187276432&u=http%3A%2F%2Fwww.fluencetraining.com%2F&a=www.fluencetraining.com)\n \n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training-302875218.html\n(https://www.prnewswire.com/news-releases/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training-302875218.html)\n\nSOURCE Fluence International, Inc.\n\n\n\nmedia@fluencetraining.com\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1980975/fluence_header_logo.jpg?id=OA2927665\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-10T12:00:16.476467652Z","server_sent_at_ms":1789041616476},"received_at":"2026-09-10T12:00:16.534Z","source_url":"https://www.prnewswire.com/news-releases/fluence-selected-by-compass-pathways-to-develop-post-approval-comp360-provider-training-302875218.html"},"analysis":{"id":"129156","press_release_id":"140339","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["COMP360 remains investigational and is not FDA approved; the training program is contingent on a future approval","No financial terms of the training grant disclosed","Release issued by private partner Fluence, not by the filer itself"],"eventType":"partnership","narrative":"Compass Pathways (Nasdaq: CMPS) selected psychedelic-therapy educator Fluence to develop a post-approval provider training certificate program for COMP360, its investigational synthetic psilocybin treatment for treatment-resistant depression.\n\nThe program prepares clinicians to support patients through the COMP360 treatment experience ahead of potential FDA approval and commercial availability, and progresses through three modules: Foundations of Psychedelic Care, Understanding Psilocybin, and COMP360 Certification.\n\nFluence was chosen through a competitive process and will combine its clinician-training experience with Compass' clinical guidance; the move signals Compass is building commercial launch infrastructure, though COMP360 is not yet FDA approved and no financial terms of the grant were disclosed.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Launch-readiness signal for CMPS — provider training buildout ahead of the COMP360 FDA decision, but a minor item; the real catalyst remains the approval itself."},"keyFigures":{"drugName":"COMP360","customDimensions":{"indication":"treatment-resistant depression","training_modules":3}},"quotedText":"This is a moment Fluence has been preparing for since our earliest days","namedEntities":{"people":[{"name":"Elizabeth Nielson, PhD","role":"CEO and Co-Founder of Fluence"}],"products":["COMP360","Post-Approval COMP360 Psilocybin Certificate Program"],"companies":[{"name":"Compass Pathways plc","ticker":"CMPS","relationship":"filer; grant provider and clinical-guidance partner for COMP360 provider training"},{"name":"Fluence International, Inc.","relationship":"training partner selected via Compass' grant program; press release issuer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Compass is investing in post-approval provider training for COMP360, a modest launch-readiness signal ahead of a potential FDA approval. No financial terms, no clinical or regulatory milestone, and COMP360 remains investigational, so the direct near-term impact on the filer is limited."},"tickerRelevance":{"others":[],"primary":"CMPS"},"globalImportance":22,"audienceRelevance":30,"eventTypeSecondary":["operations_update"],"importanceComponents":{"note":"Press release authored by Fluence (private training provider), with CMPS named as the grant provider","tickerTier":"small-cap biotech","eventGravity":"partnership / commercial-readiness step","sectorWeight":"pre-commercial biotech, approval-dependent","issuerAuthored":false,"retailFavoriteBoost":"moderate — psychedelic-sector retail following"}},"event_type":"partnership","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":2,"narrative":"Compass Pathways (Nasdaq: CMPS) selected psychedelic-therapy educator Fluence to develop a post-approval provider training certificate program for COMP360, its investigational synthetic psilocybin treatment for treatment-resistant depression.\n\nThe program prepares clinicians to support patients through the COMP360 treatment experience ahead of potential FDA approval and commercial availability, and progresses through three modules: Foundations of Psychedelic Care, Understanding Psilocybin, and COMP360 Certification.\n\nFluence was chosen through a competitive process and will combine its clinician-training experience with Compass' clinical guidance; the move signals Compass is building commercial launch infrastructure, though COMP360 is not yet FDA approved and no financial terms of the grant were disclosed.","key_figures":{"drugName":"COMP360","customDimensions":{"indication":"treatment-resistant depression","training_modules":3}},"named_entities":{"people":[{"name":"Elizabeth Nielson, PhD","role":"CEO and Co-Founder of Fluence"}],"products":["COMP360","Post-Approval COMP360 Psilocybin Certificate Program"],"companies":[{"name":"Compass Pathways plc","ticker":"CMPS","relationship":"filer; grant provider and clinical-guidance partner for COMP360 provider training"},{"name":"Fluence International, Inc.","relationship":"training partner selected via Compass' grant program; press release issuer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-10T12:03:32.543Z","global_importance":22,"audience_relevance":30,"importance_components":{"note":"Press release authored by Fluence (private training provider), with CMPS named as the grant provider","tickerTier":"small-cap biotech","eventGravity":"partnership / commercial-readiness step","sectorWeight":"pre-commercial biotech, approval-dependent","issuerAuthored":false,"retailFavoriteBoost":"moderate — psychedelic-sector retail following"}},"durationMs":31833,"modelName":"glm-5.3-flash"}}